GLB-007

GLB-007 is a preclinical molecular glue degrader (MGD) developed by Hangzhou GluBio Pharmaceutical for the treatment of sickle cell disease and beta-thalassemia. It functions by inducing the proteasomal degradation of WIZ (Widely Interspaced Zinc Finger Motifs) and ZBTB7A (Zinc finger and BTB domain-containing protein 7A), which are key transcriptional repressors of fetal hemoglobin (HbF). By eliminating these repressors, GLB-007 promotes the reactivation of HbF production, which can compensate for the defective or missing adult hemoglobin in patients with these genetic blood disorders. This small-molecule approach aims to provide a potentially more accessible, oral alternative to current gene therapy treatments for hemoglobinopathies.